Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism-Reference-Cited by-同舟云学术

Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism

Published:2016-06-21 Issue:6 Volume:11 Page:e0157509
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Grimshaw Charles E.^ORCID,Jennings Andy,Kamran Ruhi,Ueno Hikaru,Nishigaki Nobuhiro,Kosaka Takuo,Tani Akiyoshi,Sano Hiroki,Kinugawa Yoshinobu,Koumura Emiko,Shi Lihong,Takeuchi Koji

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference29 articles.

1. Organization WH. Diabetes Fact Sheet No 312: World Health Organization; 2015. Available from: http://www.who.int/mediacentre/factsheets/fs312/en/.

2. SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial;N Inagaki;Lancet Diabetes Endocrinol,2014

3. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes;DJ Drucker;Lancet,2006

4. DPP-4 inhibitors: pharmacological differences and their clinical implications;A Ceriello;Expert Opin Drug Saf,2014

5. Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study;N Inagaki;The lancet Diabetes & endocrinology,2015

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Structure-property Relationships of Clinically Approved Protease Inhibitors;Current Medicinal Chemistry;2024-04

2. Discovery of novel heterocyclic derivatives containing oxadiazolone or pyrimidinone cores as DPP‐4 inhibitors;Journal of Heterocyclic Chemistry;2024-03-23

3. Pharmacokinetics, Pharmacodynamics, and Safety of Single Dose HSK7653 Tablets in Chinese Subjects with Normal or Impaired Renal Function;Clinical Pharmacokinetics;2024-01-06

4. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, and Dose-Increasing Study on the Safety, Tolerability and PK/PD of Multiple Doses of HSK7653 by Oral Administration in Patients with Type 2 Diabetes Mellitus in China;Diabetes Therapy;2023-11-06

5. Impacts of trelagliptin and remogliflozin alone and in combination with Alpha Lipoic Acid on cardiac function in streptozotocin-induced diabetes mellitus in rats;Cellular and Molecular Biology;2023-09-30